Abstract: The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.

Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: A buoy system for treating cardiac valve regurgitation comprising a movable plug having atrial and ventricular ends, wherein a through-hole passes from the atrial to the ventricular end, wherein during systole, the plug travels toward a cardiac atrium, wherein during diastole, the plug travels into a cardiac ventricle; a tether having atrial and ventricular ends, wherein the tether passes through the through-hole of the moving plug, wherein the atrial end of the tether projects into an atrium, wherein the atrial end of the tether includes a cap to engage a delivery tool; at least one distal anchor located in the ventricle, wherein the distal anchor is coupled to the ventricular end of the tether, and wherein the system is percutaneously delivered and optionally recaptured via catheter and recapture tool at the cap of the tether, respectively.

Abstract: In a system and method for producing a mosaic image, a printable substrate has a front side that defines a first area and a second area. Both the first and second areas are printable. A back side of the printable substrate features a pressure-sensitive adhesive and a backing. The first area corresponds to a region of a physical matrix of regions. A source image may be printed on the first area to define a tile and an address of the tile on the matrix of regions may be printed on the second area. The tile may be peeled from the backing separately from the second area to reveal the pressure sensitive adhesive. Users may adhere a plurality of tiles to the matrix of regions at the addresses on the second areas to define the mosaic image.

Abstract: The present invention relates to PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol including the crystalline monohydrate thereof.

Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z?? Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The technology described in this document can be embodied in a headrest of a seat, the headrest including an enclosure for housing one or more acoustic transducers, and an adjustable headrest wing disposed in front of the enclosure. The headrest wing is coupled to the enclosure by a pivot, and configured to be adjusted to one of multiple positions within an angle range around the pivot. The headrest wing is also configured to support the head of a seat-occupant. The headrest further includes a connector disposed between the enclosure and a rear portion of the headrest wing. The connector is configured to provide an acoustic channel between the enclosure and the headrest wing such that audio signals from the one or more acoustic transducers are radiated outward through the headrest wing.

Abstract: An object with an icon thereon encodes a bit sequence. The icon comprises a plurality of concentric rings, each of the plurality of concentric rings is divided into a plurality of data sectors. Each of the plurality of data sectors is associated with a corresponding bit in the bit sequence, and each of the plurality of data sectors encodes the corresponding bit based on the presence or absence of a line segment in the sector. The plurality of concentric rings further comprises at least three anchor sectors on one or more of the plurality of concentric rings, the at least three anchor sectors comprise an anchor mark. The plurality of concentric rings further comprises one or more error correction sectors, each of the one or more error correction sectors encodes a corresponding error correction bit based on the presence or absence of a line segment in the error correction sector.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: An improved pool skimmer is provided in which a skimmer basket grapnel having a pair of aligned removable paddles adapted for attachment to a skimmer basket sidewall and for blocking suction within a skimmer basket volume. The paddles each include a vertically sliding gate which, when opened, released vacuum within the skimmer basket. This allows the basket to be easily removed. The sliding gate stems articulate vertically to open and close. The apex of the stems attaches to a handle, whereupon an upward pulling motion actuates the two paddle gates open. Once a vacuum seal is broken, the attachment to the basket sidewall allows further upward motion to remove the basket from its skimmer housing. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z?? Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: The present invention relates to methods of using compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: A detection system includes a planar plasmonic element for analyzing an analyte, the plasmonic element having dielectric and metallic regions, the plasmonic element emitting light that carries detected information; and a planar two-dimensional image sensor positioned in non-parallel angled relationship with respect to a plane of the plasmonic element to enhance a spatial image resolution for the light that carries detected information with respect to at least a portion of the light.